Systolic hypertension and cardiovascular risk reduction: A clinical review

Current Hypertension Reports

Volumn 3, Issue 1, 2001, Pages

  Cushman, William C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DECISION MAKING; HUMAN; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR; SYSTOLE; UNITED STATES;

ADULT; AGE FACTORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DECISION MAKING; HUMANS; HYPERTENSION; MIDDLE AGED; PREVALENCE; RISK FACTORS; SYSTOLE; UNITED STATES;

EID: 0035459577     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-001-0066-y     Document Type: Review

References (21)

1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997, 157: 2413-2446.
2. Burt VL, Whelton P, Roccella E, et al.: Prevalence of hypertension in the U. S. adult population. Results from the third National Health and Nutrition Examination Survey. 1988-1991. Hypertension 1995, 25: 305-313.
3. Franklin SS, Jacobs MJ, Wong ND, et al.: Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives. Analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001, 37: 869-874.
4. Lloyd-Jones DM, Evans JC, Larson MG, et al.: Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Hypertension 1999, 34: 381-385.
5. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316, 099 white men. Arch Intern Med 1992, 152: 56-64.
6. Franklin SS, Khan SA, Wong ND, et al.: Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999, 100: 354-360.
7. Sagie A, Larson MG, Levy D: The natural history of borderline isolated systolic hypertension. N Engl J Med 1993, 329: 1912-1917.
8. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351: 1755-1762.
9. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265: 3255-3264.
10. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992, 304: 405-412.
11. Dahlof B, Lindholm LH, Hansson L, et al.: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338: 1281-1285.
12. Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997, 350: 757-764.
13. United Kingdom Prospective Diabetes Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998, 317: 703-713.
14. Estacio RO, Jeffers BW, Gifford N, Schrier RW: The effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(suppl 2): B54-B64.
15. Black HR, Elliott WJ, Neaton JD, et al., for the CONVINCE Research Group: Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2001, 37: 12-18.
16. Whelton PK, Appel LJ, Espeland MA, et al.: Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998, 279: 839-846.
17. Hansson L, Lindholm LH, Niskanen L, et al., for the Captopril Prevention Project (CAPPP) study group: Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. Lancet 1999, 353: 611-616.
18. Hansson L, Lindholm LH, Ekbom T, et al., for the STOP-Hypertension-2 study group: Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 (STOP-2) study. Lancet 1999, 354: 1751-1756.
19. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000, 283: 1967-1975.
20. Hansson L, Hedner T, Lund-Johansen P, et al., for the NORDIL Study Group: Randomized trial of calcium antagonist compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet 2000, 356: 359-365.
21. Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356: 366-372.